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Abstract
Background: Angiotensin II (Ang II) signaling occurs via two major receptors which activate non-receptor tyrosin
kinases that then interact with protein tyrosin-phosphatases (PTPs) to regulate cell function. SHP-2 is one such
important PTP that also functions as an adaptor to promote downstream signaling pathway. Its role in Ang II
signaling remains to be clarified.
Results: Using cultured normal human fibroblasts, immunoprecipitation and western blots, we show for the first
time that SHP-2 and PLCb1 are present as a preformed complex. Complex PLCb1 is tyr-phosphorylated basally and
Ang II increased SHP-2-PLCb1 complexes and caused complex associated PLCb1 tyr-phosphorylation to decline
while complex associated SHP-2’s tyr-phosphorylation increased and did so via the Ang II type 1 receptors as
shown by Ang II type 1 receptor blocker losartan’s effects. Moreover, Ang II induced both increased complex
phosphatase activity and decreased complex associated PLCb1 tyr-phosphorylation, the latter response required
regulator of G protein signaling (RGS)-2.
Conclusions: Ang II signals are shown for the first time to involve a preformed SHP-2-PLCb1 complex. Changes in
the complex’s PLCb1 tyr-phosphorylation and SHP-2’s tyr-phosphorylation as well as SHP-2-PLCb1 complex
formation are the result of Ang II type 1 receptor activation with changes in complex associated PLCb1 tyr-
phosphorylation requiring RGS-2. These findings might significantly expand the number and complexity of Ang II
signaling pathways. Further studies are needed to delineate the role/s of this complex in the Ang II signaling
system.
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Background
Angiotensin II (Ang II) is a major regulator of a broad
spectrum of important biological processes ranging from
vasoconstriction to inflammatory processes including
atherosclerosis and vascular ageing, which proceeds, in
part, via phosphoinositide-specific phospholipase
C (PLC) generated second messengers [1-4]. Ang II type
1 receptors couple first to PLCb1v i aG aq/11bg and
Gaq/12 bg and then to PLCg via tyrosine kinase activity
[5]. Ang II also induces phosphorylation of growth
signaling kinases by redox-sensitive regulation of protein
tyrosine phosphatases (PTPs) [6] via oxidation/inactiva-
tion and blunted phosphorylation of the PTP, SHP-2.
Ali et al [7] demonstrated that Ang II induces SHP-2
tyrosine phosphorylation and activation of its phospha-
tase activity. In addition to its phosphatase activity,
SHP-2 appears to function as a molecular adaptor as
shown by Ali et al’sr e p o r to faS H P - 2I R Sc o m p l e x[ 7 ]
as well as its adaptor function being inferred from the
substantial differences noted between dominant negative
mutant SHP-2 (mild phenotypes [8]) and SHP-2 knock-
out (severe phenotypes [9,10]). Finally, SHP-2’sp a r t i c i -
pation in Ang II signaling has also been recently
revealed through the demonstration of its central role in
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[11], another important pathway downstream of Ang II
type 1 receptor stimulation which, when activated, ulti-
mately leads to both vasoconstriction and cardiovascular
remodeling [12,13].
The previous report of a complex involving SHP-2
suggests that SHP-2 may function as part of a complex
in other pathways. The concept of and the role(s) for
complex formation has gained increasing attention as a
means to direct signals toward a particular pathway
along with reducing the likelihood of cross-talk by Gole-
biewska et al [14]. For example, they have shown that
during Gaq signaling, Gaq, rather than selecting a spe-
cific effector during stimulation, functions via separate
pools of Gaq-effector complexes [14].
During the course of investigating Ang II signaling in
our well characterized “in vivo” human model of altered
Ang II long term signaling and vascular tone control,
Bartter’sa n dG i t e l m a n ’s syndromes [13,15-19], we have
produced findings suggesting the presence of another
complex involving SHP-2. This report represents our
initial efforts to confirm and further investigate the
characteristics of SHP-2-PLCb1 interaction as pre-
formed complex and its interaction with selected aspects
of Ang II signaling. The current study was undertaken
in normal human fibroblasts and employed specific anti-
bodies to immunoprecipitate and then characterize the
resulting immunoprecipitates, i.e. anti PLCb1o ra n t i
SHP-2 immunoprecipitates of cultured fibroblast cell
lysates were probed after western blotting using anti
PLCb1, anti SHP-2 and anti phospho tyrosine antibo-
dies. In addition, we probed Ang II signaling processes
related to this complex by assessing the effects of losar-
tan, an Ang II type 1 receptor blocker, as well as by
altering, via its silencing, the levels of the regulator of G
protein signaling 2 (RGS-2), a key control element of
Ang II signaling [20,21].
Results
The effect of Ang II on PLCb1a n dS H P - 2i nh u m a n
skin fibroblasts was examined using cultured cells incu-
bated with or without Ang II (100 nM) for 1 h. The
effect of Ang II was examined by probing Western blots
(analysed by 8% SDS/PAGE gels) of cell lysates immu-
noprecipitated with either anti PLCb1 antibody or anti-
SHP-2 antibody. The figures are the results of represen-
tative experiments. antibody. The figures are the results
of representative experiments.
Figure 1A reveals a strong band upon probing the
PLCb1 immunoprecipitate of nonstimulated cells with
anti PLCb1 phospho tyrosine, which declines (-74.43%)
when cells are treated with Ang II and is restored
(-17.6% of nonstim) when cells are treated with Ang II
plus losartan. Figure 1B shows the presence of SHP-2 in
the PLCb1 immunoprecipitate in the unstimulated state
demonstrating the formation of a complex between
SHP-2 and PLCb1. Upon treatment with Ang II, the
level of SHP-2 protein in the PLCb1 immunoprecipitate
increased (+63.7%) which then declines (+34.8%) when
cells are treated with Ang II plus losartan. The absence
of any difference when probing the PLCb1 immunopre-
cipitate with anti PLCb1 demonstrates that the decline
seen in upon Ang II treatment (Figure 1A) was only due
to changes in phosphorylation. Figures 1D and 1E pre-
sent the % change relative to unstimulated cells ± SD
(N = 5 experiments) for 1A and 1B respectively.
Figure 2B shows a band upon probing the SHP-2
immunoprecipitate of nonstimulated cells with anti
SHP-2 phospho tyrosine which increases (+345.6%)
when cells are treated with Ang II and declines (+179%
of nonstimulated cells) when cells are treated with Ang
II plus losartan. Figure 2A reveals the presence of
PLCb1 protein in the SHP-2 immunoprecipitate in the
unstimulated state demonstrating the formation of a
Figure 1 Effect of Ang II and losartan on PLCb1T y r -
phosphorylation and SHP-2 content. Fibroblasts, cultured in
absence or presence of Ang II (100 nM) and Ang II (100 nM) plus
losartan (100 μM), were scraped and extracted with buffer C (see
methods). Total cell lysate (200 μg) were immunoprecipitated with
anti-PLCb1 antibody. Immunoprecipitates were subjected to
Western blotting (analysed by 10% SDS/PAGE gels) and
immunorevealed with mouse-anti-PLCb1 P-Tyr (A) and rabbit-anti-
SHP-2 (B) antibodies, before being stripped and immunorevealed
with anti-PLCb1 (mouse) (C). The figure is representative of five
separate experiments carried out in duplicate. Panels D and E
present the percent change relative to unstimulated cells ± SD (N =
5 experiments) for panel A and B respectively. Panel D: **: p <
0.0001 vs Basal; *: p = 0.003 vs Ang. Panel E: ***: p < 0.0001 vs
Basal; *: p = 0.006 vs Ang+Los; **: p = 0.002 vs Basal.
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with Ang II, the level of PLCb1 protein in the SHP-2
immunoprecipitate increased (+393.8%) which then
declines (+112%) when cells are treated with Ang II plus
losartan. Figures 2D and 2E present the % change rela-
tive to unstimulated cells and SD (N = 5 experiments)
for 2A and 2B respectively. The absence of any differ-
ence when probing the anti SHP-2 immunoprecipitate
with anti SHP-2 demonstrates that the increase seen in
upon Ang II treatment (Figure 2B) was only due to
changes in phosphorylation.
Figure 3 presents the results of incubation in the pre-
sence of vanadate. Figure 3A shows that the level of
PLCb1 phospho tyrosine increases upon phosphatase
inhibition.
Figure 3B shows that the amount of SHP-2 protein
does not change upon incubation with vanadate.
Figure 4 shows the effects of RGS-2 silencing on the
protein levels of both SHP-2 and PLCb1a sw e l la st h e
phosphorylation of PLCb1. Figure 4A shows that RGS-2
silencing abrogates the dephosporylation of PLCb1
phospho tyrosine induced by Ang II (-69%). Figure 4B
shows that silencing of RGS-2 reduces the increase of
SHP-2 protein in the PLCb1 immunoprecipitate when
cells are treated with Ang II. Figure 4C shows that
PLCb1 protein level in PLCb1 immunoprecipitate is
unaffected by RGS-2 silencing. Figures 4D and 4E pre-
sent the % change relative to RGS-2 intact and
Figure 2 Effect of Ang II on SHP-2 association with PLCb1a n d
SHP-2 Tyr-phosphorylation. Total cell lysate (200 μg) were
immunoprecipitated with anti-SHP-2 antibody. Immunoprecipitates
were subjected to Western blotting (analysed by 8% SDS/PAGE gels)
and immunorevealed with mouse-anti-PLCb1 (A), rabbit-anti-
phospho tyrosine SHP-2 (B) antibodies, rabbit anti SHP2(C). The
figure is representative of five separate experiments carried out in
duplicate. Panels D and E present the percent change relative to
unstimulated cells and SD (N = 5 experiments) for panel A and B
respectively. Panel D: **: p < 0.0001 vs Basal; *: p = 0.001 vs Ang
+Los Panel E: *: p < 0.0001 vs Basal; +: p < 0.0001 vs Ang+Los.
Figure 3 Effect of vanadate on PLCb1-Tyr-phosphorylation and
SHP-2 association. Cells were cultured in the absence or presence
of vanadate (1 mM) and total cell lysates (200 μg) were
immunoprecipitated with anti-PLCb1 antibody. Immunoprecipitates
were subjected to Western blotting (analysed by 10% SDS/PAGE
gels) and immunorevealed with mouse-anti-P-Tyr (A) and rabbit-
anti-SHP-2 (B) antibodies. The figure is representative of three
different and separate experiments.
Figure 4 Effect of Ang II on PLCb1-Tyr-phosphorylation and
SHP-2 association in RGS-2 silenced and not silenced cells. RGS-
2 not silenced (lanes a, b) and silenced (lanes c, d) fibroblasts were
incubated with Ang II (lanes b, d,) or with vehicle (lane a, c) for 1
hour as described in the Methods. Immunocomplexes were isolated
and analyzed as described in methods. Panel A is PLCb1 Phospho-
Tyrosine levels, panel B is SHP-2 protein levels and panel c is PLCb1
protein levels. The figure is representative of five separate
experiments carried out in duplicate. Panels D and E present the
percent change relative to unstimulated cells and SD (N = 5
experiments) for panel A and B respectively. Panel D: ￿: p < 0.0001
vs Basal; *: p < 0.0001 vs Ang RGS-2 Silenced; **: p < 0.0001 vs Basal
RGS-2 Silenced. Panel E: ￿: p < 0.0001 vs Basal; *: p = 0.04 vs Ang
RGS-2 Silenced; **: p = 0.001 vs Bas RGS-2 Silenced.
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4B respectively
The phosphatase activity of the SHP-2 immunopreci-
pitates of cells significantly increased in normotensive
healthy subject cells with Ang II compared to those
without Ang II (1.55 ± 0.2 versus 1.0 ± 0.2 nanomoles
per min per 200 mg cell protein immunoprecipitate, p <
0.005).
Discussion
The present study on Ang II signaling in normal human
fibroblasts has produced the first description, to our
knowledge, of the presence of a SHP-2-PLCb1complex
that responds to Ang II signaling associated events. The
presence of a SHP-2-PLCb1 complex in fibroblast from
normotensive healthy subjects was demonstrated via
immunoprecipitates obtained by incubating with either
anti PLCb1 or anti SHP-2 (Figure 1 and 2). The rela-
tionship of this complex to Ang II signaling was demon-
strated by the fact that the degree of phosphorylation of
both PLCb1 and SHP-2, was reciprocally affected by
Ang II. Incubation with Ang II caused the dephosphory-
lation of PLCb1 and the phosphorylation of SHP-2. The
effect of Ang II on these was further demonstrated by
the blocking of these changes found by incubation in
t h ep r e s e n c eo fl o s a r t a n .M o r e o v e rt h el i n k a g eo ft h e
SHP-2-PLCb1 complex to Ang II signaling events is
further strengthened by the effect of RGS-2 silencing
which blocked Ang II induced changes in the phosphor-
ylation status of the complex proteins. In addition, Ang
II incubation led to an increase in total immunoprecipi-
table phosphatase activity. That SHP-2 may act as a
phosphatase with respect to PLCb1i ss u g g e s t e db yt h e
increased PLCb1 phosphorylation in immunoprecipita-
tion experiments in the presence of vanadate to inhibit
phosphatase activity. The absence of changes upon Ang
II treatment in the amount of PLCb1 protein isolated by
anti PLCb1 immunoprecipitation demonstrates that the
altered PLCb1 tyrosine phosphorylation (Figure 1A)
found was due to changes in PLCb1 tyrosine phosphory-
lation and not due to changes in protein amount. How-
ever, this does not appear to be the case with respect to
SHP-2 immunoprecipitation as the protein levels of
PLCb1 differed among the treatments. This may be the
result of differences in free versus complex bound SHP-
2 levels in the cells.
SHP-2, participates in multiple signal transduction
cascades, including the Ras-Raf-MAP kinase, JAK/
STAT, PI3K/Akt, NF-B, and NFAT pathways [22-24]
and accumulating evidence suggests that SHP-2 also
functions as an adaptor/scaffolding. In fact Wang et al
[25] showed that SHP-2 functions in Interleukin-1 sig-
naling as a part of a complex that was dependent on
focal adhesions, which are enriched with tyrosine
kinases and SHP-2. That SHP-2 functions as an adap-
tor/scaffolding is also suggested by the disparate nature
of the effects of overexpression of mutated, catalytically
inactive SHP-2, as compared to SHP-2 knockout [22].
Using this model, Bregeon and coworkers have recently
demonstrated a central role of SHP-2 activity as a scaf-
fold protein in the regulation of RhoA-Rho kinase path-
way’s activation [11]. In fact, they found that SHP-2 is
necessary to allow the association of the tyrosine kinase
c-Abl with p190A, a RhoA activating GTPase and the c-
Abl-mediated p190A phosphorylation to maintain basal
p190A activation and consequently a low RhoA-Rho
kinase activity. In addition, this study reports that SHP-
2 phosphatase activity itself is necessary to promote
p190A dephosphorylation and inhibition in response to
Ang II via Ang II type 1 receptor activation [11], there-
fore activating or prolonging RhoA-Rho kinase path-
way’s activity. On the other hand, Ang II type 2
receptor stimulation seems to be involved in the inhibi-
tion of SHP-2 phosphatase activity as shown by the
greater effect on p190A dephosphorylation in the pre-
sence of Ang II type 2 receptor antagonist, while Ang
II-induced p190A-dephosphorylation was abolished in
the presence of the Ang II type 1 receptor inhibitor
losartan [11].
The current study identifies a preformed SHP-2-PLC
b1 complex as a part of Ang II signaling which strength-
ens the concept that preformed complexes are involved
in cell signaling systems. These complexes have been
suggested to function to direct signals toward a particu-
lar pathway along with reducing the likelihood of cross-
talk [14]. For example, it was reported that during Gaq
signaling, Gaq, rather than selecting a specific effector
during stimulation, functions via separate pools of Gaq-
effector complexes [14]. Similarly the SHP-2-PLCb1
complex identified in the present study may function in
cardiac hypertrophy via Ang II type 1 receptor stimula-
tion as PLCb1 has been implicated by Filtz et al [26].
Conclusions
The identification of a SHP-2-PLCb1preformed complex
that responds to Ang II as shown in this study is an
important first step but the role of this complex in the
Ang II signaling remains to be delineated. We are aware
that this is a limitation of the present study, however we
think that the identification of this complex and its
response to Ang II merits to be reported waiting for the
results of further experiments specifically performed to
clarify its role in the Ang II signaling. To this purpose,
one approach to understanding the role of SHP-2-
PLCb1 complex is to assess its status in two systems
with contrasting Ang II signaling. A comparison of the
complex’s levels and behavior in Bartter’sa n dG i t e l -
man’s syndromes, a human model of blunted Ang II
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[13,15-18] and activation of Ang II type 2 receptor sig-
naling [19] to the complex’s levels and behavior in
hypertensive patients, which have Ang II signaling sys-
tem and RhoA-Rho kinase pathways, biochemical, mole-
cular and clinical features opposite to those of the
Bartter’sa n dG i t e l m a n ’sp a t i e n t s[ 1 6 ] ,m i g h tp r o v i d e
insight into the complex’s role in Ang II signaling.
These studies are ongoing in our laboratory and their
results along with those from other potential studies
examining aspects such as the respective SHP-2- and
PLCb1 binding site characteristics, likely will signifi-
cantly expand the number and complexity of the signal-
ing pathways through which Ang II signals and thereby
might provide new potential targets of therapy for dis-
eases such as hypertension, diabetes and cardiovascular
disease, in which Ang II plays a major role.
Methods
Anti-P-Tyr and anti-PLCb1monoclonal antibodies were
purchased from Biosource (Prodotti Gianni, Milano,
Italy) and Upstate (Lake Placid, NY, USA), respectively
while rabbit anti-SHP-2 (C-18) polyclonal antibody was
from Santa Cruz Biotechnology (CA, USA). Protease
inhibitor cocktail was obtained from Roche Diagnostic
(Indianapolis, IN, USA). Anti-mouse and anti-rabbit sec-
ondary antibodies conjugated with horseradish peroxi-
dase (HRP) were from (Calbiochem (Darmstadt,
Germany).
Cell Culture
Skin fibroblasts from 6 healthy subjects from the staff of
the Department of Clinical and Experimental Medicine
at the University of Padova, who gave their informed
consent, were obtained via biopsy and individually cul-
tured in F-10 HAM medium with 10% fetal bovine
serum, 100 U/ml penicillin, 100 mg/ml streptomycin
and 4 mmol/l glutamine, as previously described
[19,27,28] and used after the third passage. To assess
the effects of Ang II, cells were incubated with 100 nM
Ang II for 1 hour. This concentration was chosen, since
it was clearly seen to induce Ang II signaling in previous
reports [19,29,30]. To assess the effects of phosphatase
activity on protein phosphorylation, cells were incubated
with 1 mM vanadate overnight. To examine the effect
of Ang II type 1 receptor signaling blockade, cells were
preincubated for 30 min with 100 μM losartan and then
treated as described above. This concentration was also
chosen based on a previous report [19].
Immunoprecipitation
Anti-SHP-2 and Anti PLCb1 immunoprecipitation was
done using confluent cells. These were scraped, washed
in buffer and extracted (1 h at 4°C with buffer C (20
mM Tris-HCl, pH 7.5, 10% glycerol, 1% Nonidet-P-40, 1
mM EDTA, 150 mM NaCl, 1 mM sodium orthovana-
date, protease inhibitor cocktail). After centrifugation,
200 μg of supernatant protein were diluted 1:1 in 20
mM Tris-HCl, pH 7.5, containing 1 mM sodium ortho-
vanadate and protease inhibitor cocktail, precleared with
protein A-Sepharose, and anti-SHP-2 or anti PLCb1anti-
bodies bound to protein A-Sepharose were added at 4°
C. This was then incubated overnight, immunoprecipi-
tates were washed 3× in buffer D (25 mM imidazole,
pH 7.0, 1 mM EDTA, 0.02% NaN3, 10% glycerol, 10
mM B-mercaptoethanol, 10 mg/ml leupeptin, 50 mM
PMSF), resuspended and then submitted to gel electro-
phoresis (SDS-PAGE; 8% or 10% gels), transferred by
blotting to nitrocellulose membranes and immunos-
tained with the appropriate antibodies/second
antibodies.
Phosphatase Activity
Phosphatase activity was measured at 30°C using nitro-
phenyl phosphate (pNPP) (10 mM pNPP as substrate
in 100 mM tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1 mM 2-mercaptoethanol, and PTPase immu-
noprecipitates from 200 mg cell-protein content in
Buffer D). After 10 min at 30°C, the reaction was
quenched with 950 μl of 1 M NaOH. Absorbance at
405 nm was measured and in all cases the substrate-
to-product conversion was less than 5%. All the
reagents were from Sigma (Milano, Italy). Results are
expressed as nanomoles per minute per 200 mg cell
protein immunoprecipitate.
RGS-2 Silencing
RGS-2 gene silencing was done using chemically synthe-
sized siRNA that mapped to exon 5 of RGS-2 gene
(Silencer Pre-Designed siRNA, Ambion, Austin, USA) as
previously described [27]. Fibroblasts (2 × 10
5 cells)
were plated the day before transfection in 6-well plates
in growth medium without antibiotics containing 10%
FBS. On the day of transfection, siRNA was incubated
with Lipofectamine 2000 diluted in OPTI-MEM I (Invi-
trogen, Carlsbad, USA) following manufacturer’s
instructions (Invitrogen, Carlsbad, USA). We have cho-
sen for our experimental protocol RGS-2 siRNA map-
ping for exon 5 at a concentration of 50 nmol/l and
transfected the oligos with Lipofectamine 2000 (4 mg/
ml) as previously reported [27]. Following 20 min incu-
bation at room temperature, the obtained complexes
were added drop-wise onto the cells subcultured in
replaced cell-culture medium. The cells were maintained
in a 37°C incubator until analysis. The medium was
changed to medium with no siRNA 12 h after transfec-
tion. Fluorescein-conjugated siRNA (Control (non-silen-
cing), Fluorescein, Qiagen, Hilden, Germany) with no
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tive control to exclude non-specific effects and to moni-
tor the efficiency of transfection while GAPDH siRNA
was used as positive control (Ambion, Austin, TX USA).
Silencing was assessed by western blot and found to be
44% as previously reported [27]. Horseradish peroxidase
(HRP)-conjugated (Amersham Pharmacia, Uppsala, Swe-
den) antibody was used as secondary antibody and
visualized with chemiluminescence, which was captured
on radiograph film. Exposed films were digitized by
scanning densitometry and protein levels were calcu-
lated using National Institutes of Health (NIH) Image
software (NIH, Bethesda, Maryland, USA). b actin was
used as housekeeping gene and the ratios between RGS-
2a n db actin western blot products were used as index
of RGS-2 protein expression and expressed as densito-
metric arbitrary units.
Statistical analysis
Data were evaluated statistically as normally distributed
continuous variables and comparisons were performed
using one-way ANOVA (Statistica, Statsoft Inc, Okla-
homa City, OK, USA). Results with p < 0.05 were con-
sidered significant and data values are presented as
mean±SD.
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